Agios Pharmaceuticals, Inc. (AGIO) — SEC Filings
Agios Pharmaceuticals, Inc. (AGIO) — 27 SEC filings. Latest: 10-Q (Oct 30, 2025). Includes 9 8-K, 8 SC 13G/A, 6 10-Q.
View Agios Pharmaceuticals, Inc. on SEC EDGAR
Overview
Agios Pharmaceuticals, Inc. (AGIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 30, 2025: Agios Pharmaceuticals, Inc. reported a net loss of $103.433 million for the three months ended September 30, 2025, a significant decline from the net income of $947.915 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $304.742 million, compared to a
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 24 neutral, 1 mixed. The dominant filing sentiment for Agios Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Agios Pharmaceuticals, Inc. (AGIO) has filed 6 10-Q, 9 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A with the SEC between Jan 2024 to Oct 2025.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of AGIO's 19 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $12.880M |
| Net Income | $-103.433M |
| EPS | N/A |
| Debt-to-Equity | 0.08 |
| Cash Position | $92.710M |
| Operating Margin | -906.7% |
| Total Assets | $1.386B |
| Total Debt | $0.00 |
Key Executives
- Brian Goff
- Jacqualyn A. Fouse
- Jacqualyn A. Fouse, PhD
Industry Context
The biotechnology sector continues to focus on developing novel therapies for rare diseases and unmet medical needs. Companies like Agios are investing heavily in R&D to advance their pipelines, facing intense competition and lengthy regulatory review processes. The success of a company often hinges on the approval and commercialization of a few key drug candidates.
Top Tags
10-Q (4) · pharmaceuticals (4) · institutional-ownership (4) · executive-compensation (3) · corporate-governance (3) · 8-k (3) · amendment (3) · Rare Disease (2) · board-changes (2) · governance (2)
Executive Compensation
From the most recent DEF 14A filing (Apr 26, 2024):
- Jacqualyn A. Fouse, PhD — Member
- Brian Goff — Member
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $103.433M | Compared to $947.915M net income in Q3 2024 |
| Net loss for nine months ended Sep 30, 2025 | $304.742M | Compared to $770.248M net income in 2024 |
| Product revenue, net for Q3 2025 | $12.880M | Increased from $8.964M in Q3 2024 |
| Product revenue, net for nine months ended Sep 30, 2025 | $34.061M | Increased from $25.768M in 2024 |
| Research and development expenses for Q3 2025 | $86.796M | Increased from $72.455M in Q3 2024 |
| Research and development expenses for nine months ended Sep 30, 2025 | $251.479M | Increased from $218.476M in 2024 |
| Gain on sale of contingent payments | $889.136M | Recognized in Q3 2024, absent in Q3 2025 |
| Milestone payment from oncology business sale | $200.000M | Recognized in Q3 2024, absent in Q3 2025 |
| Regulatory milestone payment to Alnylam | $10.0M | Recorded in R&D expenses in 2025 |
| Extended PDUFA goal date for PYRUKYND sNDA | Dec 7, 2025 | Originally September 7, 2025 |
| Q2 2025 Product Revenue | $7.0M | Increased from $0.0M in Q2 2024, indicating successful PYRUKYND commercialization. |
| H1 2025 Product Revenue | $13.0M | Increased from $0.0M in H1 2024, showing strong year-to-date growth. |
| Central Index Key (CIK) | 0001439222 | Unique identifier for Agios Pharmaceuticals with the SEC. |
| Conformed Period of Report | 2025-06-30 | The financial period covered by this 10-Q filing. |
| SEC File Number | 001-36014 | Identifies the company's filing with the SEC. |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in Agios Pharmaceuticals for the foreseeable future.","entity":"The Vanguard Group","targetDate":"2025-12-31","confidence":"high"}
- {"claim":"Agios Pharmaceuticals, Inc. stock price may experience downward pressure in the short term.","entity":"Agios Pharmaceuticals, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Other institutional investors may re-evaluate their positions in Agios Pharmaceuticals, Inc. following Farallon's exit.","entity":"institutional investors","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Agios Pharmaceuticals, Inc. (AGIO)?
Agios Pharmaceuticals, Inc. has 27 recent SEC filings from Jan 2024 to Oct 2025, including 9 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AGIO filings?
Across 27 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 24 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Agios Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Agios Pharmaceuticals, Inc. (AGIO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Agios Pharmaceuticals, Inc.?
Key financial highlights from Agios Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AGIO?
The investment thesis for AGIO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Agios Pharmaceuticals, Inc.?
Key executives identified across Agios Pharmaceuticals, Inc.'s filings include Brian Goff, Jacqualyn A. Fouse, Jacqualyn A. Fouse, PhD.
What are the main risk factors for Agios Pharmaceuticals, Inc. stock?
Of AGIO's 19 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Agios Pharmaceuticals, Inc.?
Recent forward-looking statements from Agios Pharmaceuticals, Inc. include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Agios Pharmaceuticals for the foreseeable future.","ent and 2 other predictions.